PKM and malignant colon neoplasm: PKM2 has been shown to enhance the expression of PD-L1 in the LPS-activated macrophages and colon cancer-infiltrating CD1b+CD4/80+ macrophages [71]; targeting the PKM2 with a synthetic compound, Tepp-46, reduced the PD-L1 expression in macrophages and dendritic cells [71].